Seven Stars X Star Pupil by Massmedicalstrains
Seven Stars × Star Pupil
Seven Stars X Star Pupil is a hybrid cannabis strain developed by MassMedicalStrains. It is bred from a cross of Seven Stars and Star Pupil genetics, aiming to provide both reliable medical relief and a superior cultivation experience. This strain is noted for its balanced indica and sativa influences.
Appearance
Seven Stars X Star Pupil produces dense buds with a thick coating of trichomes, giving them a sparkling appearance. The buds often display a mix of deep greens and muted purples, highlighted by bright orange pistils. Advanced microscopy indicates high resin production levels, suggesting suitability for medicinal and recreational use.
Aroma & Flavor
The aroma of this strain is complex, combining earthy and woody notes with subtle citrus undertones, hints of pine, and spice. When consumed, it offers a flavor profile dominated by citrus and pine, with earthy tastes and a pleasant, mild sweetness that lingers. The smoke is often described as smooth and free from harshness.
Effects
Users commonly report a balanced experience characterized by a potent euphoric head-high alongside deep body relaxation. The strain is known to promote feelings of calmness and focus. These effects are attributed to its well-balanced genetic makeup and cannabinoid profile.
Terpenes & Cannabinoids
Terpene analysis shows a dominance of limonene, pinene, and myrcene, which contribute to the strain's sensory profile and potentially modulate its effects. The cannabinoid content typically ranges from 18% to 22% THC with less than 1.2% CBD. Minor cannabinoids like CBG and CBC may also be present, potentially enhancing therapeutic benefits.
Origins & Lineage
Developed by MassMedicalStrains, Seven Stars X Star Pupil is a hybrid resulting from the crossbreeding of the 'Seven Stars' and 'Star Pupil' strains. The breeding focused on combining stable growth traits, robust resin production, and desirable medical efficacy from its parent genetics. It was initially released in early 2021.